Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 2
1997 6
1998 11
1999 7
2000 15
2001 15
2002 4
2003 9
2004 10
2005 6
2006 6
2007 2
2008 8
2009 4
2010 5
2011 10
2012 8
2013 4
2014 6
2015 9
2016 7
2017 7
2018 13
2019 10
2020 8
2021 10
2022 11
2023 16
2024 10
2025 10
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

216 results

Results by year

Filters applied: . Clear all
Page 1
Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer.
Stahler A, Modest DP, Stintzing S, Borelli B, Keller T, Held S, Fischer von Weikersthal L, Müller L, Graeven U, Decker T, Heintges T, Kahl C, Hoppe B, Kiani A, Kaiser F, Schwaner I, Fruehauf S, Karthaus M, Trarbach T, Klauschen F, Horst D, Cremolini C, Heinemann V. Stahler A, et al. Among authors: karthaus m. J Clin Oncol. 2026 Jan;44(1):31-41. doi: 10.1200/JCO-25-00596. Epub 2025 Nov 18. J Clin Oncol. 2026. PMID: 41252656
Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trial.
Molassiotis A, Jordan K, Karthaus M, Dranitsaris G, Roeland EJ, Schwartzberg L, Stimamiglio V, Alonzi A, Olivari Tilola S, Bonizzoni E, Brozos Vázquez E, Buchler T, Cheng Y, Christoph DC, García Alfonso P, Lu X, Majem M, Mavroudis D, Syrigos K, Tomlins E, Zhou Z, Zimovjanová M, Aapro M. Molassiotis A, et al. Among authors: karthaus m. Ann Oncol. 2026 Feb;37(2):260-270. doi: 10.1016/j.annonc.2025.10.017. Epub 2025 Oct 17. Ann Oncol. 2026. PMID: 41110696 Free article. Clinical Trial.
Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216).
Lutz MP, Ansorge N, Barmashenko G, Bauer H, Burkart C, Decker T, Ettrich T, Fischer von Weikersthal L, Geer T, Gerhardt A, Höfling S, Jacobasch L, Koenigsmann M, Leidig T, Plentz R, Räth S, Reichert D, Schulte M, Schulte N, Schwarzer A, Siegler G, Waldschmidt D, Karthaus M. Lutz MP, et al. Among authors: karthaus m. Br J Cancer. 2026 Jan;134(1):85-91. doi: 10.1038/s41416-025-03188-x. Epub 2025 Oct 14. Br J Cancer. 2026. PMID: 41087530 Free PMC article. Clinical Trial.
An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: lessons from the PREDICT trial.
Lahusen A, Lutz MP, Fang R, Kirchner M, Albus S, Kluck K, Karthaus M, Schwarzer A, Siegler G, Kleger A, Ettrich TJ, Becher A, Höfling S, Siveke JT, Budczies J, Tannapfel A, Stenzinger A, Cheung PF, Eiseler T, Seufferlein T. Lahusen A, et al. Among authors: karthaus m. Mol Cancer. 2025 Jul 22;24(1):202. doi: 10.1186/s12943-025-02406-7. Mol Cancer. 2025. PMID: 40696453 Free PMC article. Clinical Trial.
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer.
Elez E, Yoshino T, Shen L, Lonardi S, Van Cutsem E, Eng C, Kim TW, Wasan HS, Desai J, Ciardiello F, Yaeger R, Maughan TS, Morris VK, Wu C, Usari T, Laliberte R, Dychter SS, Zhang X, Tabernero J, Kopetz S; BREAKWATER Trial Investigators. Elez E, et al. N Engl J Med. 2025 Jun 26;392(24):2425-2437. doi: 10.1056/NEJMoa2501912. Epub 2025 May 30. N Engl J Med. 2025. PMID: 40444708 Free PMC article. Clinical Trial.
2024 update of the AGIHO guideline on diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients with solid tumours and hematological malignancies.
Sandherr M, Stemler J, Schalk E, Hattenhauer T, Hentrich M, Hertenstein B, Hohmann C, Mellinghoff SC, Mispelbaum R, Rieger C, Schmidt-Hieber M, Sprute R, Weiss G, Cornely OA, Henze L, Lass-Floerl C, Beutel G, Classen AY, Freise NF, Karthaus M, Koehler P, Krause R, Neuhann J, Orth HM, Penack O, Schaich M, Spiekermann K, Voigt S, Weissinger F, Busch E. Sandherr M, et al. Among authors: karthaus m. Lancet Reg Health Eur. 2025 Jan 31;51:101214. doi: 10.1016/j.lanepe.2025.101214. eCollection 2025 Apr. Lancet Reg Health Eur. 2025. PMID: 39973942 Free PMC article. Review.
Panitumumab plus 5-fluorouracil and folinic acid or 5-fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer (PanaMa, AIO KRK 0212): final efficacy analysis of a randomised, open-label, phase 2 trial.
Stahler A, Karthaus M, Fruehauf S, Graeven U, Müller L, Fischer von Weikersthal L, Caca K, Goekkurt E, Ballhausen A, Sommerhäuser G, Alig AHS, Held S, Jarosch A, Horst D, Reinacher-Schick A, Kasper S, Heinemann V, Stintzing S, Trarbach T, Modest DP. Stahler A, et al. Among authors: karthaus m. EClinicalMedicine. 2024 Dec 16;79:103004. doi: 10.1016/j.eclinm.2024.103004. eCollection 2025 Jan. EClinicalMedicine. 2024. PMID: 39802302 Free PMC article.
216 results